Legend Capital's portfolio company Xbiome Inc., an industry-leading and AI-driven microbiome therapeutics company, recently announced that it acquired the clinical-stage M201 program from Assembly...
Legend Capital's portfolio company Lunit, a Korean Medical AI company, recently announced a preliminary approval from the Korea Exchange for initial public offering (IPO)...
Shanghai Langsheng Biotechnology Co., Ltd., a subsidiary of Legend Capital's co-founded company Innostellar Biotherapeutics, announced that the clinical trial application of its product LX101...
On 31 March 2022, Legend Capital's portfolio company Jiangsu Recbio Technology Co., Ltd. (Recbio, HKG: 2179), a leading novel vaccines company, went public on...
On 28 February 2022, Inceptio Technology, an autonomous driving truck technology and operation company, announced its completion of a US$188 million Series B+ equity...
On December 14, Legend Capital portfolio company SF Intra-city (09699.HK) successfully listed on the Hong Kong Stock Exchange (HKEx). SF Intra-city issued a total...
Recently, Zhuhai Sailner 3D Technology Co., Ltd. (Sailner 3D), a leading industrial-grade color 3D printing company with independent core technology in China, announced its...
